J&J ASCO 2026: PROTEUS and Tecvayli data

Key Takeaways

• PROTEUS (NCT03767244): pCR/MRD 8.9% vs 1.0% (OR 10.17); 20% lower risk of metastasis or death (HR 0.80) at median 61.7 months follow-up.
• PROTEUS opened the ASCO 2026 plenary (LBA1) and published simultaneously in NEJM on 31 May 2026.
• MajesTEC-9 (NCT05572515): Tecvayli cut PFS risk 71% (HR 0.29) and OS risk 40% (HR 0.60) versus PVd/Kd.
• Secondary valuation chatter (P/E screens, street targets) is not primary evidence and is excluded from this brief.

What did PROTEUS change for high-risk localized prostate cancer?

J&J reported final Phase 3 PROTEUS results on 31 May 2026: six months of apalutamide plus ADT before and after radical prostatectomy versus ADT plus placebo. Dual primary endpoints both met. Patients were about nine times more likely to have little or no residual cancer at surgery (8.9% vs 1.0% pCR/MRD). Metastasis or death risk fell 20% (HR 0.80; 95% CI 0.67–0.96; p=0.02), with five-year metastasis-free rates 78.2% vs 73.5%.

Source the company wire on PR Newswire’s PROTEUS release and the peer-reviewed report in NEJM: Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Which PROTEUS safety numbers matter for BD risk models?

Grade 3 or 4 adverse events occurred in 39.6% on apalutamide plus ADT versus 31.0% on ADT alone, driven partly by rash. Discontinuations for adverse events were 7.4% vs 2.7%. Common events included hot flush (63.4%), urinary incontinence (50.2%), and erectile dysfunction (41.6%).

• Median follow-up: 61.7 months
• pCR/MRD OR: 10.17 (95% CI 5.27–19.64)
• MFS HR (BICR): 0.80
• Investigator MFS HR: 0.74
• ClinicalTrials.gov: NCT03767244

How did MajesTEC-9 position Tecvayli earlier in myeloma?

At ASCO 2026, MajesTEC-9 showed Tecvayli monotherapy versus PVd or Kd in RRMM after 1–3 prior lines including lenalidomide and a CD38 antibody. In a largely anti-CD38- and lenalidomide-refractory population, Tecvayli reduced progression or death risk by 71% and death risk by 40%. Complete response or better reached 65.9% vs 16.8%.

Trial registration: ClinicalTrials.gov NCT05572515 (MajesTEC-9). PROTEUS registration: NCT03767244.

What remains unproven for equity valuation narratives?

Neither PROTEUS nor MajesTEC-9 discloses a company-issued price target, P/E multiple, or discounted cash-flow model. Street targets and screener multiples are secondary and can lag label, REMS, and competitive dynamics. Treat ASCO data as clinical depth for oncology franchise diligence, not as a finished valuation.

How should competitive intelligence teams use the package?

For prostate cancer, perioperative intensified ADT plus ARPI now has Phase 3 metastasis-free evidence at surgery-intent stages. For myeloma, bispecific monotherapy moves earlier with OS and PFS superiority versus common triplets/doublets. Cross-check labeled Tecvayli and Erleada indications on FDA resources before modeling off-label uptake.

FDA labeling database entry point: FDA Drugs@FDA.

Related NovaPharma coverage

• Biopharma news: approvals, appeals, AI — week of June 2026
• FDA gene therapy guidance: industry-friendly draft for BD
• Pfizer berobenatide obesity drug: VESPER-3 data

Frequently Asked Questions

Primary Sources

1. PR Newswire: PROTEUS Phase 3 apalutamide results
2. NEJM: Perioperative Apalutamide in High-Risk Localized Prostate Cancer
3. ClinicalTrials.gov: PROTEUS NCT03767244
4. ClinicalTrials.gov: MajesTEC-9 NCT05572515